Q1-FY24 · Glenn Saldanha
We should be able to meet our guidance or even exceed our guidance this year.
GLENMARK / language trends
Read confidence between the lines.
Glenmark Pharmaceuticals · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q1-FY24 · Glenn Saldanha
Europe will be a big driver for us... at least a 25%-30% growth coming on a full year basis out of Europe.
Q1-FY24 · Glenn Saldanha
A critical event for us obviously is to get past Monroe and get that going.
Q1-FY25 · Glenn Saldanha
The U.S. business continues to remain challenging, but I think the second half of this year, right, once we get our respiratory products approved, right, I think that's when you'll really see the recovery.
Q1-FY25 · Glenn Saldanha
Given the European performance, right, we are thinking that the European business could be as big as, almost as big as the US business by the end of this year.
Q1-FY25 · Glenn Saldanha
Our goal with IGI is to get to POC and, you know, we are seeing some very good data on 2001, which we will present at ASH.
Q1-FY26 · Glenn Saldanha
We are very confident that the India business growth will be strong. I think post-Q3, you should see the numbers play out quite significantly.
Q1-FY26 · Anurag Mantri
Q3 onwards, the EBITDA margin trajectory should stabilize close to a 23% + range. 23% is what we are guiding.
Q1-FY26 · Glenn Saldanha
We are hoping that this year we will restart commercial manufacturing. That's our view on Monroe.
Q2-FY24 · Utkarsh Gandhi
We are considering this year as a transition year on account of the GLS divestment, which has obviously been a big event.
Q2-FY24 · Glenn Saldanha
U.S. is a big unknown. We are doing the right things in terms of portfolio, but you know, given the uncertainties, we really struggle to put any number for the U.S. business.
Q2-FY24 · Glenn Saldanha
In the month of October, we grew 19%, right, as per IMS. So India business, we think, from here on, right, will come back strongly.
Q2-FY25 · Glenn Saldanha
We believe that this will have a long runway, right? So this is our second or third year of launch, and we're tracking at about $80 million annual sales. And this will keep growing rapidly, right, to becoming a $200-plus million product, right, over the next three to five years.
Q2-FY25 · Glenn Saldanha
I think this is the first time we have a real world-class asset, right, which can be transformational in the multiple myeloma space.
Q2-FY25 · Glenn Saldanha
We had a meeting with the agency on the Monroe facility specifically, and we are pretty positive about the agency visiting us and reinspecting. And we think by before the end of this year, there's a strong possibility we may reinitiate commercial production.
Q2-FY26 · Glenn Saldanha
Post Q2, Glenmark is entering a new phase called Glenmark 3.0. I see Glenmark in the next 5 to 10 years as a glorious phase for the firm.
Q2-FY26 · Glenn Saldanha
The ISB 2001 deal clearly vindicates our years of investment in innovation. With this deal and with the receipt of INR 700 million, we are able to pay down all our debt, and we're net cash positive.
Q2-FY26 · Anurag Mantri
We have now made a very standard process of the provisioning norms. Going forward, I can assure you... we have now made it on a basis of principles.
Q3-FY24 · Glenn Saldanha
We've done a lot of restructuring, right? This is all part of the overall restructuring that we are doing in terms of our innovation across the company, right? And with this heightened focus and synergies that will come out of this alliance, right, we believe there will be a significant improvement in terms of our bond, right, on innovation.
Q3-FY24 · Glenn Saldanha
Next year's EBITDA number, right, you'll see a significant bump-up. This is one of the key drivers. But in addition, also, because of Ryaltris and some of the other operating leverage that we are seeing in geographies like Latin America, Europe, which has always been a low-margin business for us now with the scale that we are gaining in Europe and Latin America, right, all that should help drive EBITDA strong next year.
Q3-FY24 · Glenn Saldanha
We think this will be the next Ryaltris for the company. So the next 3 years-4 years, we think Ryaltris will dominate, and thereafter, envafolimab can be the next Ryaltris for us, right, especially operating in a very large market.
Q3-FY25 · Glenn Saldanha
ISB 2001 is a super exciting product, right, and has the ability to be a transformational asset for Glenmark and probably the entire multiple myeloma space, right, given the data we put out at ASH.
Q3-FY25 · Glenn Saldanha
If I look out to FY 2026, we have two major launches in the first half of FY 2026. One is, of course, Fluticasone 44 MDI, right, Flonase, where we believe we have an exclusive position.
Q3-FY25 · Glenn Saldanha
Our view is FY 2026 will be the last year where Glenmark will have to put capital into IGI.
Q3-FY26 · Glenn Saldanha
RYALTRIS will be a $100 million product for us this year and continues to scale as we go forward.
Q3-FY26 · Anurag Mantri
We remain confident of closing FY 26 on a strong note and foresee a good start off to our next growth journey of Glenmark 3.0 from 2027 onwards.
Q3-FY26 · Glenn Saldanha
The next five years continue to remain pretty exciting for Glenmark in terms of growth, performance across all the parameters.
Q4-FY24 · V. S. Mani
We are hoping that in first quarter, they will come in the next couple of months, I'm guessing.
Q4-FY24 · V. S. Mani
We believe that we are the first filer on this product, okay? So, I mean, it's launch on approval, basically, right?
Q4-FY24 · V. S. Mani
FY 26 will be a big year for the company. That's what we believe, right, in terms of overall growth, right, top line growth.
Q4-FY25 · Glenn Saldanha
We think a deal for 2001 will really be transformational for Glenmark, right? It will overshadow anything else that we are doing in the near term.
Q4-FY25 · Glenn Saldanha
Overall, the business continues to do well, right? ROW is strong. Europe is seeing strong growth.
Q4-FY25 · Glenn Saldanha
The two big players are Keytruda, is the biggest there, right, which pretty much dominates the market. Then we have Nivolumab, right, of Bristol.